Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | POLQ | O75417 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21838602 | 1.00 | KMO (0.37) | KMOPOLQAKR1C3AKR1C1NOTUM | |
| SCHEMBL21838628 | 0.92 | AKR1C3 (0.44) | POLQAKR1C3AKR1C1HSD11B1 | |
| SCHEMBL21838644 | 0.92 | SCN9A (0.39) | HSD11B1SCN9A | |
| SCHEMBL21838629 | 0.90 | SCN9A (0.45) | SCN9A | |
| SCHEMBL21838645 | 0.90 | SCN9A (0.45) | SCN9A | |
| SCHEMBL21838609 | 0.88 | SCN9A (0.41) | SCN9AOPRM1OPRD1 | |
| SCHEMBL21838555 | 0.81 | HSD11B1 (0.40) | POLQHSD11B1SCN9A | |
| SCHEMBL21838579 | 0.78 | NOTUM (0.34) | KMOPOLQNOTUMHSD11B1 | |
| SCHEMBL21838543 | 0.76 | HTR2C (0.41) | AKR1C3AKR1C1HSD11B1 | |
| SCHEMBL21838600 | 0.76 | HTR2C (0.41) | AKR1C3AKR1C1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | KMO 1181/4885POLQ 4083/4885AKR1C3 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.